What Raciper-D Treats: Main Uses and Benefits

Raciper-D is used to manage a range of symptoms and conditions related to excess stomach acid and slowed movement in the upper digestive tract. The medicine is indicated for providing relief from symptoms such as persistent heartburn, acid regurgitation, indigestion, and difficulty swallowing caused by acid reflux.

It is commonly utilized in clinical practice to manage symptoms associated with conditions including gastroesophageal reflux disease (GERD), stomach and intestinal ulcers, and Zollinger-Ellison syndrome.

Patients may experience symptom management and a reduction of discomfort, which can support improved daily comfort and overall well-being. Management of these conditions primarily focuses on symptom control.

---

Quick Fact: Relief for Acid Regurgitation

Who can and cannot use Raciper-D?

The population eligibility for Raciper-D, a medicine combining Esomeprazole and Domperidone, is strictly defined by regulatory authorities, largely based on the Domperidone component's cardiac safety profile. This medicine is contraindicated in several specific patient groups:

• Cardiac Conditions: Patients with existing prolongation of cardiac conduction intervals (QTc), congestive heart failure, or significant electrolyte disturbances (e.g., hypokalemia).
• Organ Function: Individuals with moderate or severe hepatic impairment must not use this medicine. Use in severe renal impairment is restricted and requires a reduced dosing frequency.
• Gastrointestinal Issues: Patients with conditions where motility stimulation is harmful, such as gastro-intestinal haemorrhage, obstruction, or perforation.

Age and Special Populations

Raciper-D is approved for adults and adolescents 12 years of age and older and weighing at least 35 kg. It is not recommended for children under 12 years of age. Use in patients older than 60 years requires caution. Furthermore, the medicine is not recommended for use during pregnancy or lactation due to the transfer of the Domperidone component into human milk.

Interactions with other medicines and products

The interaction profile of Raciper-D is governed by the official restrictions for its two active components, Esomeprazole and Domperidone.

Formal Contraindicated Combinations

Co-administration is formally contraindicated with medicines that pose a significant QTc-prolonging risk, such as certain antiarrhythmics and antipsychotics, due to an additive pharmacodynamic effect. The Domperidone component is also contraindicated with potent CYP3A4 inhibitors (e.g., specific macrolides and systemic azole antifungals), as these substantially increase its plasma exposure. The Esomeprazole component is officially contraindicated with Rilpivirine-containing products.

Pharmacokinetic and Exposure Constraints

Esomeprazole acts as an inhibitor of CYP2C19, which officially decreases the exposure of the active metabolite of Clopidogrel, leading to a formal restriction on their co-use. Due to this same mechanism, co-administration may elevate the serum concentrations of drugs like Methotrexate and Tacrolimus. Medicines that rely on gastric pH for absorption, such as Digoxin, may have altered bioavailability, potentially increasing their exposure. Concomitant use with CYP inducers like St. John’s Wort is officially advised against due to reduced Esomeprazole plasma levels.

Procedural and Food Constraints

Food intake officially delays and decreases the absorption of both active components. Furthermore, the drug must be temporarily stopped prior to assessing Chromogranin A (CgA) levels, as the medicine officially interferes with this diagnostic test.

Irreversible Blocking of Acid Production

This mechanistic domain involves the component that acts as an irreversible inhibitor of the H^+/ K^+-ATPase enzyme (the proton pump) in the stomach lining. By permanently binding to this enzyme within the parietal cells, the drug blocks the final step of acid secretion, resulting in a reduction in gastric acidity.

---

Modulating Gut Movement and Sensory Signals

This mechanism centers on the drug component that acts as a competitive antagonist at D2 dopamine receptors. This antagonism occurs both peripherally in the digestive tract and centrally in the Chemoreceptor Trigger Zone. This action removes the inhibitory influence of dopamine on gut muscle tone, thereby increasing the rate and coordination of gastric transit. The central action contributes to suppressing the initiation signals of the emetic reflex via the D2 receptors in the brainstem.

How to Use Raciper-D

This section describes the administration and dosing principles for Raciper-D (Esomeprazole/Domperidone).

---

Administration Protocol

The medicine is designed for oral administration as a capsule, typically formulated with both enteric-coated and sustained-release (SR) components. The capsule must be swallowed whole with a glass of water and must not be crushed or chewed. This instruction is procedural, intended to maintain the integrity of the capsule's specialized coating and ensure the correct release of the active ingredients.

Administration is typically scheduled to occur once daily, preferably in the morning. To achieve optimal absorption of the Esomeprazole component, the capsule is taken on an empty stomach or approximately 30 to 60 minutes **before a meal.

---

Dosing and Duration Principles

The standard adult regimen is one capsule once daily. The most common strengths available include Esomeprazole 40 mg / Domperidone 30 mg or 20 mg / 30 mg. Treatment with this fixed-dose combination is generally intended for short-term use. This time-limited principle reflects considerations associated with the chronic use of the Domperidone component.

High-level dose modifications apply to specific populations. For patients with severe hepatic impairment, the maximum daily dose of Esomeprazole may be limited (e.g., to 20 mg). In cases of severe renal impairment, the dosing frequency for the Domperidone component may need to be reduced.

Research evidence / Overview of studies for Raciper-D

---

Evidence for Use in Gastroesophageal Reflux Disease (GERD)

Research has explored the use of this fixed-dose combination in adults experiencing symptoms of Gastroesophageal Reflux Disease (GERD) and in populations where erosive esophagitis was studied. Evidence was gathered primarily from short-term Randomized Controlled Trials (RCTs) and systematic reviews that compared the combination therapy class (PPI plus a prokinetic agent) to taking a PPI alone. Studies generally examined patient-reported experiences, using research exploring how symptoms change over time, and also monitored objective outcomes linked to changes in the inner lining of the esophagus.

The short-term studies monitored patient responses over defined time intervals, typically ranging from two to eight weeks, during periods of increased symptom activity. Research highlights changes measured during the study period, focusing on outcomes related to physical discomfort such as heartburn and acid regurgitation.

---

Evidence for Symptom Management in Dyspepsia

The combination was studied for its relevance in managing symptomatic dyspepsia (common indigestion symptoms) when this condition is associated with acid reflux. The research examined and was evaluated in observational settings evaluating daily-life functioning, often using prospective clinical trials focused on patients reporting discomfort. Studies monitored outcomes related to functional imbalance and physical discomfort, such as bloating, post-prandial fullness, and upper abdominal pain.

Research limitations were noted because the evidence base frequently relies on single-center or observational study designs. Limited high-level data exists specifically comparing this combination against other therapies used for functional dyspepsia in large-scale reviews.

---

Research Landscape for Specialized or Extra-Esophageal Conditions

This medicine was evaluated in highly targeted, specialized research, such as studies focusing on children with difficult-to-treat asthma where GER was a confirmed comorbidity in the study population. Studies reported how symptoms evolved in the observed populations over intermediate follow-up periods of approximately three months. Data presented variable patterns in relation to objective respiratory measures, and data show patterns related to patient-reported experiences.

---

What is Still Uncertain About the Combination

Research has explored symptom patterns over defined time intervals, but follow-up durations were limited in the primary efficacy trials. Long-term effects are not fully established, and this is an area where data are still emerging. Comparative evidence is lacking in large-scale reviews for several outcomes. Furthermore, certain primary research studies have modest sample sizes, and there is limited information for long-term outcomes, meaning certainty remains low regarding sustained effects and maintenance patterns.

Key Studies & References

1. National Institute for Health and Care Excellence (NICE): Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (NG17)

How to Store and Dispose of Raciper-D

Official regulatory guidelines define specific conditions to maintain the stability and safety of Raciper-D (Rabeprazole and Domperidone).

Storage Requirements

The medicine must be stored at controlled room temperature, typically below 25 C or 30 C, and must be kept from freezing. The capsules require protection from environmental factors; they must be stored in a dry place and protected from light and moisture.

Keep the medicine in its original container and ensure it is tightly closed until use. A mandatory safety instruction requires keeping Raciper-D out of the sight and reach of children and pets.

Disposal

To prevent environmental contamination, do not flush expired or unused Raciper-D down the toilet or throw it into the drain. Unused medicine must be discarded properly following local guidelines for pharmaceutical waste.